000915 Shandong Wit Dyne Health
- 32.26
- -0.83-2.51%
Shandong Wit Dyne Health News
Walter Dyne (000915.SZ): Icexin Vitamin AD drops are the company's main product
Gelonghui, May 13 | Walter Dyne (000915.SZ) said on the investor interactive platform that Ecoxin Vitamin AD drops are the company's main product and have been ranked first in the market share of similar products for many years. Using the broad influence of the “Eikexin” brand, the company has also built a series of children's health products such as “Icexin” children's nutrition products, children's health foods, and children's health products.
Walter Dyne (000915.SZ) plans to pay 20 yuan for 10 shares to be exempted from interest on May 16
Walter Dyne (000915.SZ) announced that the company's 2023 equity distribution plan: to all shareholders for every 10...
Guohai Securities released a research report on April 21 stating that it gave Walter Dyne (000915.SZ) a purchase rating. The main reasons for the rating include: 1) strong R&D strength, focusing on the field of child health; 2) intelligent upgrading promo
Guohai Securities released a research report on April 21 stating that it gave Walter Dyne (000915.SZ) a purchase rating. The main reasons for the rating include: 1) strong R&D strength, focusing on the field of child health; 2) intelligent upgrading promotes production chain optimization and production capacity improvement. (Mainichi Keizai Shimbun)
Walter Dyne (000915): Continued development of new products, steady growth in performance
Incident: On April 18, 2024, Walter released its report for the first quarter of 2024: the company achieved revenue of 572 million yuan in the first quarter of 2024, an increase of 1.85% over the previous year; achieved a net profit of 1.69 million yuan
Express News | Walter Dyne: Net profit of 169 million yuan in the first quarter of 2024 increased 3.0% year-on-year
Walter Dyne (000915) 2023 Annual Report Review Report: Rich Product Layout, Steady Performance Growth
Incident: Walter released its 2023 annual report on March 16, 2024: In 2023, the company achieved revenue of 2,484 billion yuan, an increase of 6.11% over the previous year; achieved net profit of 585 million yuan to mother.
Waltdyne (000915.SZ) children's drugs mainly include iKexin vitamin AD drops, edicine, desloratadine oral solution, etc.
Gelonghui, March 19 | Walter Dyne (000915.SZ) said on the investor interactive platform that the company's children's drugs mainly include iKexin vitamin AD drops, eDexin, dyne iron, dyne calcium, dyne zinc, oral rehydration solution, pediatric ibuprofen suppositories, atomoxetine hydrochloride oral solution, and desloratadine oral solution. Among them, Icexin Vitamin AD drops had the largest sales of all products. “Yikexin” is a well-known trademark in China and has been ranked first in the market share of similar products for many years.
Walter Dyne (000915): Optimistic about high dividends, new volume, and steady growth
Key investment points In 2023, the company will continue to focus on the main pharmaceutical industry. We are optimistic about the company's core products (iKexin) and key second-tier products (dyne iron, dyne calcium, pediatric ibuprofen suppositories, etc.) channel expansion and continuous improvement in penetration rate, and the product matrix will continue to be rich
Walter Dyne (000915) 2023 Annual Report Review: Focus on the steady growth of the main business and significantly increase the dividend ratio
Incident: The company released its 2023 annual report, achieving revenue, net profit attributable to mother, and net profit excluding non-return to mother of RMB 24.84/5.85/571 million yuan respectively, an increase of 6.11%/11.08%/7.86% over the previous year. Sutra
Walter Dyne (000915.SZ): Net profit for 2023 increased 11.08% to 585 million yuan, plans to pay 10 to 20 yuan
Gelonghui, March 15 | Walter Diamond (000915.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 2,484 billion yuan, up 6.11% year on year; net profit attributable to shareholders of listed companies was 585 million yuan, up 11.08% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 571 million yuan, up 7.86% year on year; basic income per share was 2.50 yuan; it plans to distribute a cash dividend of 20 yuan (tax included) to all shareholders for every 10 shares.
Walter Dyne (000915.SZ) Performance Report: Net profit for 2023 was 584 million yuan, up 10.82% year-on-year
Gelonghui, January 19 | Walter Dain (000915.SZ) announced the 2023 annual results report. In 2023, the company achieved total operating income of 2,474 billion yuan, up 5.68% year on year; total profit of 1,323 billion yuan, up 14.15% year on year; net profit attributable to shareholders of listed companies was 584 million yuan, up 10.82% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 564 million yuan, an increase of 6.52% year on year; basic earnings per share were 2.49 yuan.
Walter Dyne (000915.SZ): The existing production capacity can fully meet the needs of various markets for products
GLONGHUI January 16 | Walter Dyne (000915.SZ) said on the investor interactive platform that the company's current production capacity can fully meet the needs of various markets for products.
Walterdyne (000915.SZ): The rapid growth of pediatric ibuprofen suppositories had a positive impact on the company's annual performance growth
Glonghui December 20 | Walterdyne (000915.SZ) said on the investor interactive platform on December 20 that in recent years, sales of pediatric ibuprofen suppositories have been in line with expectations, and the growth rate has been relatively good. The rapid growth of pediatric ibuprofen suppositories has had a positive impact on the company's annual performance growth, but since it previously accounted for a relatively small share of the company's drug sales, the impact is not significant at this stage.
Walterdyne (000915.SZ): Dyne Pharmaceutical obtains drug registration certificate for atomoxetine hydrochloride capsules
Glonghui December 8 | Walterdyne (000915.SZ) announced that recently, Shandong Dyne Marine Biopharmaceuticals Co., Ltd. (Dyne Pharmaceutical for short), a subsidiary of Shandong Walterdyne Health Co., Ltd., received the “Drug Registration Certificate” (certificate number: 2023S01930) for atomoxetine hydrochloride capsules issued by the State Drug Administration. This product is used to treat attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.
Walterdyne: Sales of pediatric ibuprofen suppositories were good this year, growing rapidly
Glonghui, December 6 | Walterdyne said on the investor interactive platform on December 5 that sales of pediatric ibuprofen suppositories have been good this year and are growing rapidly. Influenza has been frequent recently, and the incidence of colds and fevers is rising, which will also boost sales of fever-reducing drugs.
Walterdyne (000915.SZ): Currently, Dyne Pharmaceuticals does not produce azithromycin granules
GLONGHUI December 5: Walterdyne (000915.SZ) stated on the investor interactive platform that currently Dyne Pharmaceuticals does not produce azithromycin granules. The sales situation of pediatric ibuprofen suppositories this year has increased significantly compared to previous years. Both medical institutions and retail pharmacies sell them.
Walterdyne (000915.SZ): Dyne Pharmaceuticals products are aimed at children aged 1-3 and are administered rectally
On December 5, Walt Dyne (000915.SZ) stated on the investor interactive platform that Dyne Pharmaceutical products target children aged 1-3 and are administered rectally. They are suitable for children with fever caused by the common cold or influenza to relieve children with mild to moderate pain such as headache, arthralgia, migraine, toothache, muscle pain, and neuralgia in children.
Walterdyne (000915.SZ): Currently, the utilization rate of various production plants is high, and there is no overcapacity problem
Glonghui November 13: Some investors asked Walterdyne (000915.SZ) on the investor interactive platform, “Does this mean that there is a problem of overcapacity or low capacity utilization?” The company replied that the company made medium- to long-term construction plans for the production base in accordance with the development strategy, and that the production capacity design was in line with market expectations for the company's products. Currently, the utilization rate of various production workshops is high, and there is no overcapacity problem.
Walterdyne (000915.SZ): Intends to transfer 51% shares of Dyne Health and Dyne Hi-Tech
On October 26, Huatedyne (000915.SZ) announced that the third interim meeting of the company's 10th board of directors in 2023 deliberated and passed the “bill on the transfer of the 51% equity agreement held by Shandong Dyne Marine Biopharmaceutical Co., Ltd. to Shandong Huatdyne Health Co., Ltd. to Shandong Huatdyne Health Co., Ltd.” and the “bill on the transfer of the 51% equity agreement held by Shandong Dyne Hi-Tech Children's Pharmaceutical Research Institute Co., Ltd. to Shandong Huatdyne Health Co., Ltd.” Agree to the company's transfer of Beijing Dyne Health
Walterdyne (000915.SZ): No azithromycin granules were produced
Glonghui, Oct. 24 | Walterdyne (000915.SZ) said on the investor interactive platform that the company currently does not produce azithromycin granules.
Analysis
Price Target
No Data
